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Mycophenolic acid (MPA) , a n inhi bito r of purine synthes is, was eva luated for its 
t hera peut ic a nd adverse effects in 29 patien ts with psorias is. 
MPA was adm inistered ora lly for at least 12 weeks, during which t im e t he daily dose was 
increased from 1600 to 4800 mg depending on occurrence of adverse react ions. 
Complete clearin g occurred in 1 of t he patients, a lmost complete clea rin g in 14, definite 
improvement in 13, s li g~ t or doubtfu l impro vement in 1. T he fu ll effect of MPA required a 
med ia n t ime of 8 weeks (range 5- 14). Afte r discont inuing MPA, re lapses began a t a med ia n 
time of 4 weeks (range 3- 8). The severi ty of psorias is was scored on a 0 to 108 sca le using a 
newly dev ised system . The mea n seve rity and ra nge before t reatment was 47 (21- 88); after 12 
weeks, 15 (0- 50). 
Adjustment of dose on t he basis of s ide effects resul ted in a med ia n da ily dose of 3600 mg 
(range 2400- 4800 mg; 30- 96 mg/kg idea l weight). Characteristic dose- limit ing side effects were 
soft or freq uent bowel movements, diarrhea , nausea, a nd ano rex ia. One insta nce of 
revers ible, dose- related leukopenia was identifi ed . 
Experience has shown t hat drugs which s low 
cellul a r replication may h.ave a benefi cial effect on 
psori as is when ad ministered systemica lly. In re-
cen t years, systemic admi'nistration of metho-
trexate [2-6 ], hydroxyurea [7,8], azaribi ne [9- 12], 
or other ant imeta boli tes [13, 14 ] has achieved some 
degree of effi cacy in suppressing the activity of 
psoriasis. Adverse reactions a nd other prob lems 
en countered with the drugs used to date indicate 
tha t t he sea rch should cont inue for a more satis-
factory psoriasis suppressant. Drugs t hat a re safer 
and more selective in their action, a nd thereby 
mor e practical to uSe, a re the objects of this sea rch. 
Mycophenoli c acid , a weak orga nic ac id, is one of 
severa l phenoli c fermentation products of Penicil-
lium stoloni(erum and was na med by Alsberg and ' 
Black in 1913 [15 ]. A similar, if not identica l, 
phenol had been isolated from the broth of a 
cult ure of P. glaucum in 1896 by Gozio [16]. The 
cOIllplete structu re of mycophenoli c ac id was re-
ported in 1952 by Birkinshaw et a l [1 7 ] and is 
shown in Figure 1. Limited a nt ibiotic and a nt ifun · 
gal activity of the compound was detected [18,19] 
and it was noted to have in vitro a nt ivira l 
activ ity [20 ], as well as the ability to inhibit virus-
induced Rous sarcoma a nd Friend leukemia in 
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vivo. Sweeney a nd co·workers were a ble to demon-
stra te that mycop henolic acid was active aga inst 
severa l so lid murine tumors, but was in act ive 
against murine leukemias [21,22 ]. 
In vitro biochemica l studi es have demonstrated 
that mycophenoli c ac id in te rfers with t he synt hes is 
of guanos ine monophosphate, a purine precursor of 
RNA a nd DNA . Adenosine monophosphate syn-
t hesis is not inhibi ted by t he drug. Specifica lly, 
mycop henoli c acid inhibi ts inos ine monophos-
pha te dehydroge nase whi ch conve rts in os ine 
monophosphate to xa nt hosine monophosphate, 
and gua nos ine monophosphate synt hetase, which 
converts xanthosine monophosphate to guanosine 
monophosphate [23 ]. These sites of metabolic 
blockade are illustrated in Figure 2. 
Free mycophenolic acid is lipid soluble and 
ra p!'dly absorbed a fte r ora l administration . On ly 
one- ha lf of a 60 mg/kg ora lly adm inistered dose of' 
[Ue ]mycophenoli c ac id was detected in the gas-
trointestina l tract of t umor-bea ring C3H mice after 
15 min , t he ti me at which max imum blood levels 
were obse rved. Rats, mice, and ma rmosets were 
fed t he labeled compound a nd placed in res pirome-
ter cha m bers; no "C0 2 was detected in the exp ired 
a ir , indicating t hat myco pheno lic ac id is not meta -
bolica lly degraded. N inety percen t of' t he adminis-
tered radioactiv ity was found in t he urine a nd feces 
within 24 hr [23 ]. Simi lar data were obta ined 
ut ilizing parenterally administered water-soluble 
monosodium mycop henolate. 
Preclinica l tox icologic stud ies with t his com· 
pound provide evidence of a wide margin of safety . 
The acu te LD . o of ora lly adm inistered myco-
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Flc. 1. Stru cture of mycophenolic acid. 
phenoli c ac id in mice is 1917 mg/kg (SE ± 232), 
and in rats, 452 mg/kg (SE ± 36) [24 ]. In our 
laboratories no cl in ical, laborato ry, o r autopsy 
evidence of tox ic ity was found in rabbits t hat 
recei ved 320 mg/kg/ day for one yea r (GC Todd , 
unpublished data). P relimina ry clinical tr ia ls in 37 
patients with a var iety of a dvanced malignant 
tumors, t hough failing to demonstrate s ignifi can t 
ant it umor effect, establis hed t hat doses of up to 
6400 mg da il y were re lat ively free from tox ic 
effects. The re was no ev idence in a ny patient of 
drug- induced leukopenia , t hrombocytopen ia, he-
molysis, or liver damage [25 ]. In another se ries of 23 
patients wit h neop last ic disease, gastro in test ina l 
intoleran ce was noted at high doses , but no other 
clinical or laboratory abnorma li ties were iden t ifi ed 
[26 ]. 
Lintrup et a l [27 ] have studied t he metabolism of 
myco phenolic ac id given ora lly a nd parenterally. 
Their data indicate t hat. foll owing a s ingle intrave-
nous dose of t he sod ium sa lt, concentrations of free 
mycophenolate fall rap idly, with a measured ha lf-
li fe of 4 mi n after a dose of 500 mg, and 12 min after 
a dose of 1000 mg. Ora l doses of 1000 mg resu lted in 
maximum serum concentrat ions at 1 hr which fe ll 
to negligible leve ls at 4 hr. In patients rece iv ing t he 
com pound both parenterally a nd ora lly, exc retion 
was rap id and essent ia ll y complete within 24 hr. 
All myco phenoli c acid recovered in t he urine was 
in t he form of t he glucuronide conjugate . 
These studies underscore a unique and very 
desirable type of t issue selectiv ity which was 
s uspected in ea rl y tissue cul tu re screenin g 
experiments [28 ]. Free mycophenolic ac id exerts a 
significant anti proliferative effect; mycop henoli c 
ac id glucuronide shows no such effect. When 
admi nistered systemica lly, the free drug is rapidly 
converted by t he li ver to t he inactive glucuronide 
which cannot penet rate cell m embranes . Theoreti-
ca lly , in t issues such as hum a n ep idermis, which 
contain a hi gh degree of act ivity of beta 
glucuronidase [29], the glucuron ide is hydrolyzed 
to free a nd act ive mycop henoli c ac id whi ch can 
exe rt a loca lized effect. Only t hose a nim al t umors 
that have very high levels of hypoxanthine- guanine 
phosphoriboxyltransferase a nd are able to bypass 
the m ycophenolic acid block are drug resistant [23 ]. 
This communication reports t he resu lts of a pilot 
study which was undertaken over a period of 11/1 
yea rs in a group of 29 patients with psoriasis. The 
objectives of t he study were as follows : (1) to 
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determine t he m ax imum dose leve ls t hat could b e 
tolerated by patients with psoriasis and t he char-
acteri st ic s ide effects produced by such doses; (2) 
to determine wha t dose leve ls, if a ny, might 
suppress psori as is; (3) to obta in other informatio n 
concerning the drug's cha racte ristics, such as t ime 
needed for full effect and durat ion of remissions 
that wou ld be useful in des igning further studie~ 
for proving t he effect iveness and studying t h e 
safety of long-term use . 
MATERIALS AND METHODS 
Subjects. Only patients with psori as is who were unabl e 
to achi eve sa t isfacto ry results with conventional therapy 
other than methotrexate were admitted to the study. 
Informed written consent was obta ined from eac h su b_ 
ject . All subtypes of psorias is, including th e plaque, 
guttate, inverse, pustul ar, palmar, nail. and a rthrit ic 
types, were considered sui tab le for study. Dermatologists 
in the Indianapolis and Miami areas were in vited to refe r 
patients with severe psorias is to the clini ca l investigators. 
The protocol excluded the foll owing groups of patients 
from the study: (1) premenopausa l women with chil d_ 
bea ring potential; (2) children under 12 yea rs of age; (3 ) 
patients receiv ing methotrexate, unt il t he drug had bee n 
discont inued for at least. 30 days; (4) patients with 
preex ist ing leukopenia. 
The study population included 22 women and 7 men' 
15 of the patient.s had rece ived prior therapy wi t h 
methotrexate. The patients ranged in age from 27 to 84 
with a mean age of 52. Their mea n weight was 162 pounds 
(range 100-232) whi ch co mpared with an " idea l" weigh t 
(data from Metropolitan Life Insurance Co., New York) 
of 133 pounds (range 107- 180) . The mea n extent of body 
area in volved before treatment was 23 % (range 3- 67) a nd 
the mean severity score (see below) before treatme nt was 
47 (range 21- 88). Activity of disease was considered 
"severe" if greater tha n 10% involvement was ev ident ; 3 
patients with less than \0% involvement had disabling ' 
palmoplantar psoriasis. 
Treatment . Appl ication of bland emmoli ents such as 
petrolatum or hyd rophylic ointment USP was permitted 
during the study period if needed for relief of itchi ng and 
burning. The few pati ents who were allowed to co ntinue 
the sparing use of topical corticostero id crea ms or oin t_ 
ments in the study period were observed for a minimulll. 
pretreatment period of 1 month , and mycophenolic ac id 
therapy was begun on ly after the severit.y had sta bi li zed 
Topical therapy was interd icted in those areas ut ilized i~ 
scoring severity of disease . 
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F lc. 2. Sites of metabolic blockade. Mycophenolic acid 
(MPA ) blocks the in terconversions or inosine-5'-phos_ phate (IMP) to xanthosine-5' -phosphate (XMP), and 
xa nt hos ine-5' -p hosphate to gua nos ine-5' -phosphate 
(GMP). ADS = adenylosucc ini c ac id ; AMP = adenosine_ 
5' -phosphate. (Figure part ially reproduced from Whee ler 
GP, Alexander JA, Cancer Res. 21:390, 1961.) 
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Mycophenolic acid was supplied in 400·mg capsules. 
Previous experience with the drug indicated that a 
minimum starting dose of 1600 mg per day would be 
tolerated [26]. For hospita lized patients (3 of the 29) a 
maximum dose of 9600 mg per day was chosen because of 
t he likelihood of gastrointestina l adverse reactions at or 
above this dose. For outpatients (26,), the arbitra ry 
maxi mum dose was 4800 mg per day . D~ il y divided doses 
were prescribed a t 6· , 8· , or 12· hr in tervals. Dosa ge was 
increased stepwise, depending upon response, not less 
than every 2 days, but genera lly once eac h week . For 
t h ose patients unable to tolerate 4800 mg per day , the 
dosage was adju sted downward to the maximum dose 
t hat could be tolerated without adverse reactions. The 
maximum continuous treatment period was limi ted to 12 
weeks. A 4·week rest period ela psed before a second 
course was sta rted. Ten patients who used t he drug at 6· 
o r 8-hI intervals were given a second 12·week course us ing 
12-hr dose intervals, to compare the relative effectiveness 
and tolerance of t he two regimens. 
M e asu.rem ent of disease seuerity. Before, during, and 
after treatment, the severity of psori as is was scored using 
a standardi zed syste m. Each of 6 selected representative 
s kin s ites was graded quantitatively for t he degree of 
e ryth e ma, sca ling, a nd t hickening on a sca le of 0 to 6 (0 = 
absen t, 1 = trace , 2 = mild , 3 = mild to moderate, 4 = 
mode rate, 5 = moderate to severe, 6 = severe) . Represent· 
ative s ites were usually selected from areas of predilec· 
t io n in 6 zones, viz, t he occipital sca lp, the extensor 
surface of an arm or an elbow, the lumbar area, the knee, 
and 2 other s ites, including a na il f'o ld , and a palm oplan· 
tar s urface, if' involved . The total "severity score" at eac h 
observation was reco rded as the sum of the 18 individual 
scores and was expressed on a 0 to 108 sca le. The perce nt 
of body area involved with eryth ema and scaling was 
est imated at the beginning and at the conclusion of the 
t reatm ent . Pruritus and pain , when prese nt, were a lso 
recorded on a sca le of 0 to 6, but were not in cluded in the 
severi ty score; patients were observed and scored at least 
weekly during the first 8 weeks, then every 2 weeks. 
post-treatment observat ions were made at intervals of 2 
to 4 weeks to document the duration of' remiss ions. 
A du erse reactions. Using a check list, patients were 
quest io ned at each visit concernin g adverse reactions, 
particularly those rela ted to t he gastrointest in al tract, 
t h e urinary t ract , and the centra l nervous system. Labo· 
ratory ex aminations were made a t least once wee kly 
duri n g the first 8 weeks and inclu ded co mplete blood 
counts , BUN, serum uri c ac id , to tal bilirubin, tota l 
protein. a lbumin , a lk aline phos phatase, SGOT , LDH , 
glucose, cholesterol , ca lcium, phosphorus, urina lys is, a nd 
stoo l exa minat ions for occult bl ood . As the study pro· 
gressed , the stoo l examinat ions were discontinued be-
60 
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FIG . 3. Decline in mea n psoriasis severity score during 
t reatment with mycophenolic aciel . 
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TABLE I. Degree of imprauem ent during t reatment with 
mycaphenolic acid 
Desc ription 
Com plete clearin g 
AI most complete clea ring 
Definite improvement 
Slight or doubtful improve ment 
No improve ment 
Worse 
Mean 
seve rit y 
sco re a rl er 
12 weeks 
o 
9 
23 
27 
Number 
of 
pat ienls 
14 
13 
1 
o 
o 
cause of predominately negative results. After 8 weeks, 
these laboratory observat ions were ma de every other 
week both while the patient received mycophenolic acid 
and during t he post-treatment period . 
RESULTS 
Most patients first noted improvement in psori a-
sis during the t hird or fourth wee k of treatment. 
Achievement of a m ax imum response to the drug 
required a media n t ime of 8 weeks (ra nge 5- 14) . 
The mean severity score of the 29 pat. ien ts dimin-
ished from 47 to 15 over the initial 12-week 
treatment period. The rate of' dec line in mea n 
severity score is s hown in Figure 3. 
The degree of' improve m ent observed with m yco-
phenolic ac id is categori zed in T a ble I. Examples 
of the clinical improve m ent a re shown in the before 
and a fte r photographs in Figure 4. 
Afte r mycophenoli c a 'id t herapy was discon-
tinued, patients gradua lly rel a psed to their former 
state of involvement. The relapse was generally 
comp lete by a median t ime of4 weeks (ra n ge 3-8). 
As the dose was progressively inc reased , most 
patients encountered adverse reactions principally 
involving the gastrointes tinal tract. Adjustmen t of 
dose on the basis of id e effects r es ul ted in a 
median d a ily dose of 3600 m g (range 2400- 4800 
mg). The m edi a n to le rated dose in t he test group 
was 65 mg/kg ideal weight (range 30-96). Obes ity 
did no t appear to increase t he pat ie nts' ab ility to 
to lerate hi gh doses. 
Several types of a dverse react ions were cha rac-
teristic of hi gh doses; they a re listed in Tabl e II in 
the order of frequency of occurrence. These reac-
tions s ubs ided qui ckly upon t e mpora ry in terrup -
t ion of t he medica tion 01' reduct io.n of dosage. 
During t he early weeks of treat m e nt, mild to 
moderate nausea frequ ently was observ ed. Late r, 
loose 0 1' frequent bowe l m oveme nts were the m ost 
common pa t ien t compla ints. Severa l women de-
veloped dysuria and were found to have s ignifica nt 
bacte riuria . These patients were treated with ap-
propri ate a ntibacterial therapy a nd subsequently 
were a ble to to lerate the medication wi t hout deve l-
opment of sympto ms referabl e to the urin a ry t ract. 
S uc h symptoms did not occur a m o ng th e male 
patients. 
One patient deve loped leukopenia (WBC 
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FIG. 4. Clini cal photographs taken before and a fter 6 to 12 weeks of treatment with mycoph enolic acid . Patients 
shown achieved a l most co mplete clea ring. 
1200) wit hin the first 7 weeks of treatmen t at a dose 
of 800 mg eve ry 6 hr ; mycop henolic ac id was 
discontinued a nd the white blood cell coun t 
promptly rose to the norm al range. Later, the 
pat ient resumed therapy at a lowe r dose, 1200 mg 
every 12 hr, and his white blood ce ll count fell to 
3900. T hrom bocytopenia of 66,000 and 90,000 
platelets/mm 3 was noted in 2 pat ients. T heir 
plate let cou nts increased pro mpt ly following d is-
conti nuation of t he medicine; both of t he patients 
subsequently were able to to lerate t he drug with-
out fur t her t hrombocytopeni a . 
T he laboratory values in a group of 20 study 
patients were tabu lated a nd exa mined for shift in 
the mean va lues. T he most striking change was the 
decline in blood uri c ac id , as illustrated in F igure 
5. T he eventual dec line from the ini t ia l mean va lue 
was a pprox imate ly 30%. 
DISCUSSION 
T he method used in t hi s stud y for quantitat in o-
pso rias is seve rity gave sat isfacto ry cons i stanc~ 
between diffe rent scorers and from week to week 
with t he same obse rver. 
Al t hough forma l proof t hat myco phenol ic ac id is 
a n effective psori as is suppressa nt will req uire dou_ 
ble-blind, placebo-cont rolled studies, our experi_ 
ence in thi s pilot study has been encouraging. 
Clea rl y, t his is a drug t hat requires ca lefu l ind ivid _ 
ualization of dose; the doses required to control 
psori a tic les ions a re close to t hose at which many 
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T ABLE II. Adverse reactions as,;ocia ted wit h h i"h doses of 
mycop f7 el1 olic acid in 29 pa tients with psoria sis 
umbe r or 
patients 
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FIG. fl. Declin e in mean blood uric acid concentration 
during treatment with ora l mycophenolic acid. 
patients expe rie nce adve rse effects. We a re confi-
dent that with fur t her clinical s tud ies of methods 
for opt imiz in g t he dosage and regim en, the thera -
peutic index of mycophenoli c acid can be in -
creased. 
Patients with act ive psorias is ha ve bee n shown 
to have hi gher mean blood uri c ac id leve ls than the 
normal population [30 ]. The decline in uric ac id 
levels observed during th is study is compatib le 
with t he improvement in psoriasis a nd the actio n 
of the drug in inhibiting purine sy n thesis . 
Ongoing an ima l tox ic ity stu d ies indicate a hi g h 
leve l of sa fety; in particular, no lon g-term hemato-
logic o r hepat ic tox ic ity has been noted to date . 
Long-term cl inica l safety studies in a larger group 
of patients a re in progress and are be ing conducted 
in para ll e l wit h double-blind, p lacebo-controlled 
efficacy studies. 
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